Brief: Maat Pharma Announces Positive Outcome Following Dsmb Review Reinforcing Confidence In Phase 3 On-Going Trial In Acute Graft-Versus-Host Disease With Maat013

Maat Pharma SA

26/10/2023 06:51

Oct 26 (Reuters) - Maat Pharma SA  MAAT.PA :
    * MAAT PHARMA ANNOUNCES POSITIVE OUTCOME FOLLOWING DSMB
REVIEW
REINFORCING CONFIDENCE IN PHASE 3 ON-GOING TRIAL IN ACUTE
GRAFT-VERSUS-HOST DISEASE WITH MAAT013
    * MAAT PHARMA SA - INDEPENDENT DATA SAFETY MONITORING BOARD
(DSMB), AFTER CAREFUL REVIEW OF SAFETY, EFFICACY, AND PROTOCOL
ADHERENCE, HAS UNANIMOUSLY RECOMMENDED THAT TRIAL CONTINUES
WITHOUT MODIFICATION
    * MAAT PHARMA SA - DSMB CONCLUDED ON A POSITIVE BENEFIT/RISK
RATIO
BASED ON A GOOD SAFETY PROFILE AND POSITIVE PRELIMINARY EFFICACY
RESULTS WITH AN OVERALL RESPONSE RATE HIGHER THAN PRE-DEFINED
PROTOCOL ASSUMPTIONS
    * MAAT PHARMA SA - NEXT MILESTONES FOR THE ARES PHASE 3
TRIAL
INCLUDE: MID-2024, PRIMARY ENDPOINT EVALUATION: GASTROINTESTINAL
OVERALL RESPONSE RATE (GI-ORR) AT DAY 28
    * MAAT PHARMA SA - NEXT MILESTONES FOR ARES PHASE 3 TRIAL
INCLUDE:
MID-2025, SECONDARY ENDPOINT EVALUATION: ONE-YEAR OVERALL
SURVIVAL

Source text for Eikon:  ID:nBw4yGDrza 
Further company coverage:  MAAT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))